SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like DBV Technologies Reports Positive Data from Milk Allergy Trial February 26, 2018 Aimmune Appoints As Chief Financial Officer April 12, 2017 Look Out Biotech! Google's Parent Sets Sights on Poaching Top Talent From Life Sciences and Healthcare April 5, 2017
Look Out Biotech! Google's Parent Sets Sights on Poaching Top Talent From Life Sciences and Healthcare April 5, 2017
